Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments

共保存肿瘤和浸润免疫区室的类器官的免疫治疗模型

基本信息

  • 批准号:
    10212018
  • 负责人:
  • 金额:
    $ 65.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-17 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The immune system remarkably distinguishes between self and non-self/self-aberrant antigens, affording exquisite anti-tumor specificity and inhibition of tumorigenesis. However, tumor immunosurveillance is unfortunately opposed by tumor cell evasion of the immune response. Immune checkpoint blockade (ICB) targeting PD-1, PD-L1, CD40 and others, as well as adoptive cell transfer (CAR-T, bulk TILs) favorably modulate this equilibrium for therapeutic benefit. However, response rates are often incomplete, progressive disease is common, and predictive biomarkers are suboptimal. The development of next-generation immunotherapies has been hindered by a lack of in vitro models that functionally recapitulate syngeneic interactions between tumor and infiltrating immune cells. In response, we have developed organoid methods that culture primary human tumor biopsies together with their infiltrating immune components as a cohesive unit without reconstitution. These “patient-derived tumor organoids” (PDO) preserve tumor cells alongside endogenous T, B, NK cells and macrophages, robustly recapitulate the T cell receptor clonotype repertoire of the original tumor, and crucially, manifest tumor-infiltrating lymphocyte (TIL) expansion, activation and tumor cell killing in response to anti-PD-1/PD-L1 therapeutic antibodies (Cell, 2018). The PDO system thus represents a holistic organoid model of human tumor-immune interactions. Here, we leverage the PDO technique to investigate immunotherapeutic mechanisms and treatments in PD-1-responsive cutaneous squamous cell carcinoma (cSCC) and melanoma, exploiting pre- and post-treatment human biopsies and mouse models. Aim 1 hypothesizes that checkpoint inhibition induces a complex and sequential network response involving immune-tumor and immune-immune crosstalk. Thus, Aim 1 employs the ability to perform serial time-course sampling of PDOs to define a single cell RNA-seq network cellular crosstalk model of the early anti-PD-1-stimulated anti-tumor immune response over multiple acute time points typically inaccessible to clinical biopsies performed after months. Importantly, comparison of this immune propagation in responding versus non-responding mouse and human organoids will define nodal points conferring resistance. Aim 2 improves bulk TIL adoptive transfer immunotherapy by using PDOs as living bioreactors to enrich tumor-reactive mouse and human melanoma TILs by anti-PD-1 checkpoint inhibition, followed by testing of enhanced anti-tumor activity in vitro and in vivo. Lastly, Aim 3 performs a co-treatment trial comparing anti-PD-1 responses of pre-treatment biopsy cSCC PDOs to clinical outcomes. Further, post- treatment biopsy PDOs are re-challenged with anti-PD-1 and a novel agent inactivating PD-1 by dephosphorylation. We thus utilize the holistic PDO model preserving endogenous tumor epithelial and immune components en bloc to investigate and improve cancer immunotherapy via our team of Calvin Kuo (organoids), Mark Davis and Chris Garcia (tumor immunology) and Anne Chang and Dimitri Colevas (cSCC clinicians).
项目摘要 免疫系统显著区分自身和非自身/自身异常抗原, 具有良好的抗肿瘤特异性和抑制肿瘤发生的作用。然而,肿瘤免疫监视是 不幸的是,肿瘤细胞逃避免疫反应。免疫检查点阻断(ICB) 靶向PD-1、PD-L1、CD 40等,以及过继细胞转移(CAR-T,散装TIL)有利地调节 这种平衡是有益的。然而,反应率往往是不完全的,进展性疾病是 常见的和预测性的生物标志物是次优的。 由于缺乏体外模型,下一代免疫疗法的发展受到阻碍 其在功能上概括了肿瘤和浸润性免疫细胞之间的同源相互作用。在答复中, 我们已经开发出类器官方法,将原发性人类肿瘤活检组织与其浸润性细胞一起培养, 免疫成分作为一个没有重建的凝聚单位。这些“患者源性肿瘤类器官”(PDO) 与内源性T、B、NK细胞和巨噬细胞一起保存肿瘤细胞, 受体克隆型库的原始肿瘤,关键是,表现肿瘤浸润淋巴细胞(TIL) 抗PD-1/PD-L1治疗性抗体的扩增、活化和肿瘤细胞杀伤(Cell,2018)。 因此,PDO系统代表了人类肿瘤-免疫相互作用的整体类器官模型。 在这里,我们利用PDO技术来研究免疫机制, PD-1反应性皮肤鳞状细胞癌(cSCC)和黑色素瘤的治疗, 治疗前和治疗后的人类活组织检查和小鼠模型。目的1假设检查点抑制 诱导涉及免疫-肿瘤和免疫-免疫串扰的复杂和顺序的网络响应。 因此,目标1采用进行PDO的连续时程采样的能力来定义单细胞RNA-seq 多种早期抗PD-1刺激的抗肿瘤免疫反应的网络细胞串扰模型 几个月后进行的临床活检通常无法获得急性时间点。重要的是,比较 在应答与非应答小鼠和人类类器官中的这种免疫传播将定义淋巴结转移。 赋予抵抗力的点。目的2通过使用PDO作为活体来改善批量TIL过继转移免疫治疗 生物反应器通过抗PD-1检查点抑制富集肿瘤反应性小鼠和人黑素瘤TIL, 随后在体外和体内测试增强的抗肿瘤活性。最后,Aim 3执行共处理 比较治疗前活检cSCC PDO的抗PD-1应答与临床结局的试验。此外,后- 用抗PD-1和一种新的PD-1灭活剂对治疗活组织检查的PDO进行再激发, 去磷酸化因此,我们利用整体PDO模型保留内源性肿瘤上皮和免疫 通过我们的卡尔文郭(类器官)团队, Mark Davis和Chris Garcia(肿瘤免疫学)以及Anne Chang和Dimitri Colevas(cSCC临床医生)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CALVIN J KUO其他文献

CALVIN J KUO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CALVIN J KUO', 18)}}的其他基金

Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
SARS-CoV-2 刺激的先天性和适应性免疫的肠道类器官模型
  • 批准号:
    10319858
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
TOOLKIT Core
工具包核心
  • 批准号:
    10272362
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
Core 2: Stanford Breast Metastasis Center Organoid Core
核心 2:斯坦福乳腺转移中心类器官核心
  • 批准号:
    10704695
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
Core 2: Stanford Breast Metastasis Center Organoid Core
核心 2:斯坦福乳腺转移中心类器官核心
  • 批准号:
    10272393
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
TOOLKIT Core
工具包核心
  • 批准号:
    10706501
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
SARS-CoV-2 刺激的先天性和适应性免疫的肠道类器官模型
  • 批准号:
    10654752
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
共保存肿瘤和浸润免疫区室的类器官的免疫治疗模型
  • 批准号:
    10374163
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
共保存肿瘤和浸润免疫区室的类器官的免疫治疗模型
  • 批准号:
    10586140
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
SARS-CoV-2 刺激的先天性和适应性免疫的肠道类器官模型
  • 批准号:
    10450851
  • 财政年份:
    2021
  • 资助金额:
    $ 65.79万
  • 项目类别:
Organoid Core B
类器官核心B
  • 批准号:
    10178731
  • 财政年份:
    2020
  • 资助金额:
    $ 65.79万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 65.79万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了